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httpVascular reconstruction plays an important role in
the treatment of pancreatic adenocarcinoma
Michael D. Sgroi, MD, Raja R. Narayan, MPH, John S. Lane, MD, Aram Demirjian, MD,
Nii-Kabu Kabutey, MD, Roy M. Fujitani, MD, FACS, and David K. Imagawa, MD, PhD, FACS,
Irvine, Calif
Objective: Previous studies have proved the feasibility of performing a pancreaticoduodenectomy (Whipple operation) in
patients with portal veinesuperior mesenteric vein and hepatic artery invasion. We report our institutional experience
with the use of a variety of vascular reconstructive methods during pancreatic resections for adenocarcinoma.
Methods: A retrospective review was performed identifying all patients undergoing a Whipple operation or total pancre-
atectomy procedure from January 2003 to December 2013. All venous (portal veinesuperior mesenteric vein) and arterial
(superior mesenteric arteryehepatic artery) reconstructions were extracted and reviewed to determine survival and
perioperative complications.
Results: During the 10-year study period, 270 Whipple and total pancreatectomy procedures were performed, of which
183 were for adenocarcinoma of the pancreas. Of the 183 operations, a total of 60 (32.8%) vascular reconstructions were
found, 49 venous and 11 arterial. Venous reconstruction included 37 (61.7%) primary repairs, four (6.7%) re-
constructions with CryoVein (CryoLife, Inc, Kennesaw, Ga), three (5.0%) repairs with autologous vein patch, three
(5.0%) autologous saphenous reconstructions, and two (3.33%) portacaval shunts. In addition, there were 11 (18.3%)
arterial reconstructions (seven hepatic artery and four superior mesenteric artery). The 1-year survival for all re-
constructions was 71.1%, which is equivalent to T3 lesions that did not receive vascular reconstruction (70.11%), with a
median survival time of 575.28 days and 12 patients still alive. Survival time was comparable with each type of venous
reconstruction, averaging 528 days (11 of 49 patients still alive). There was a total thrombosis rate of seven of 60 (11.6%),
all of which were portal vein thrombosis: three in the primary repair group and four delayed thromboses seen in primary
repair, CryoVein repair, and vein patch repair. There was no thrombosis in any patients after arterial reconstruction.
Conclusions: An aggressive approach for stage II pancreatic cancers with venous or arterial invasion can be performed with
comparable results when it is executed by an experienced institution with skilled oncologic and vascular surgeons. (J Vasc
Surg 2015;61:475-80.)Pancreatic cancer continues to be one of themost deadly
neoplasms, with amortality rate approximately equivalent to
its incidence. More than 75% of patients are not diagnosed
until they already have locally advanced disease or distant
metastases that preclude radical surgery.1-5 Asmortality rates
decreased after this highly invasive procedure, surgeons
became more aggressive in their resections. Currently,
high-volume institutions routinely perform pancreaticoduo-
denectomy with vascular reconstruction (PD þ VR) on
borderline resectable tumors. Current guidelines from thethe Division of Vascular and Endovascular Surgery and Division of
epatobiliary and Pancreas Surgery, Department of Surgery, University
California, Irvine.
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://dx.doi.org/10.1016/j.jvs.2014.09.003National Comprehensive Cancer Network state that pancre-
atic adenocarcinoma is considered borderline resectable if
there ismesenteric vascular involvement thatmay necessitate
a venous or arterial resection and reconstruction. In some
centers, resection of the portal vein, the superior mesenteric
vein, or the portal veinesuperior mesenteric vein conﬂuence
may represent up to 25% of cases with equal survival
compared with patients not requiring a VR and without ma-
jor additional perioperativemorbidity.6,7 In addition, arterial
resection has also become more common, particularly when
a replaced right hepatic artery is involved.
Despite multiple studies conﬁrming the efﬁcacy of this
operation, a recent nationwide database review argued the
opposing view.8 Not only did the authors ﬁnd evidence of
greater morbidity and mortality, but they also found no ev-
idence of improved outcomes when a vascular specialist
performed the vascular resection and reconstruction.
With this conﬂicting evidence in mind, we present one of
the largest American single-institutional studies comparing
the outcomes and survival of PD þ VR with PD only.
METHODS
Patient selection. After Institutional Review Board
approval was obtained for the study, a retrospective review
of a prospectively collected database was performed475
Fig 1. Inclusion and exclusion criteria.
Table I. Demographic data
VR
(n ¼ 60)
No VR
(n ¼ 87) P valuea
Age, years 64.5 6 10.0 67.4 6 9.7 .081
Male 32 (53.3) 43 (49.4) .641
Race/ethnicity .188
Non-Hispanic white 53 (88.3) 70 (80.5)
Non-Hispanic black 0 (0) 2 (2.3)
Hispanic 5 (8.3) 5 (5.8)
Asian or Paciﬁc Islander 2 (3.3) 10 (11.5)
Chronic conditions .423
Hypertension 27 (45.0) 45 (51.7)
Diabetes mellitus 7 (11.7) 27 (31.0)
Hyperlipidemia 7 (11.7) 15 (17.2)
Gastroesophageal reﬂux 8 (13.3) 7 (9.2)
Hypothyroidism 7 (11.7) 4 (4.6)
None 13 (22) 20 (23)
Neoadjuvant chemotherapy 23 (38.3) 8 (9.1) <.05
VR, Vascular reconstruction.
aP values are analysis of variance (continuous variables), Chi-square
(categorical variables), or Fisher exact test (where 50% or more of the cells
have expected counts less than ﬁve).
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tomy from January 2003 to December 2013 at our institu-
tion. Informed consent was not obtained as all data were
kept anonymous and personal health information was not
revealed. A total of 270 patients were identiﬁed, of
whom 183 were found to have a ﬁnal pathologic diagnosis
of pancreatic adenocarcinoma. All T1 and T2 tumors were
excluded, and only lesions that were identiﬁed as T3N0 or
T3N1 were included. This kept a consistent comparison
between the two groups. Therefore, a total of 147 patients
were identiﬁed, 87 of whom were categorized into the PD
group and 60 into the PD þ VR group (Fig 1).
Surgical technique. VRs were performed by the
Division of Vascular Surgery.
Primary repair was the most consistently used technique.
Primary repair was performed whenever it was deemed
possible. It has been well established that a generous 2- to
3-cm segment of the superior mesenteric veineportal vein
can be resected without the need for an interposition graft.9
In all other cases, an interposition graftdautologous vein or
CryoVein (CryoLife, Inc, Kennesaw, Ga)dor patch was
used. Postoperatively, patients were prescribed prophylactic
anticoagulation. Each patient was then discharged with a pre-
scription for aspirin, clopidogrel, and an antilipid medication.
Outcomes. For all adenocarcinomas, the size, margins,
and lymph node involvement were recorded, and the
American Joint Committee on Cancer Cancer Staging
Manual10 was used for staging. Survival was based on
the date of the surgery to the date of death. In patients who
are still alive, their survival time was based on an arbitrary
date of December 31, 2013, as well as a recent clinic visit or
conﬁrmation from the treating oncologist that the patient
is still alive. Perioperative death included all patients who
expired within the ﬁrst 90 days postoperatively, identifying
both 30-day and 90-day mortality. In addition, complica-
tions and predictors of survival were analyzed.
Statistical analysis. All statistical tests were two sided,
and analyses were performed with SAS version 9.3 (SAS
Institute, Cary, NC). Associations between categorical
and continuous variables were studied with c2 and Fisher
exact tests with a P value of .05 as the cutoff for statistical
signiﬁcance. The Kaplan-Meier method was employed to
estimate 1-, 3-, and 5-year survival probability between the
PD and PD þ VR groups by the log-rank (Mantel-
Haenszel) test for signiﬁcance, again determined by P values
# .05. Unadjusted bivariate and multivariate logistic
regression analysis was performed to study postoperative
complications as well as prognostic factors affecting survival.
RESULTS
A total of 183 operations were performed for pancre-
atic adenocarcinoma. Of those 183 operations, 60 required
a VR, recognizing that 32.8% of our patient population has
borderline resectable disease. The average age of patients
was equivalent between the PD and PD þ VR groups
(67.4 6 10.0 years and 64.5 6 9.7 years, respectively;
P ¼ .081), with the majority being white (80.5% vs
88.3%, respectively; P ¼ .097). There were no statisticaldifferences in any demographic category other than neoad-
juvant chemotherapy (Table I), in which there were signif-
icantly more patients within the PD þ VR group compared
with the PD-only group (38.3% vs 9.1%; P # .5).
Of the 60 VRs that were performed, 49 were venous
and 11 were arterial reconstructions. Venous reconstruc-
tion included 37 (61.7%) primary repairs, four (6.7%) re-
constructions with CryoVein, three (5.0%) repairs with
autologous vein patch, three (5.0%) autologous saphenous
reconstructions, and two (3.33%) portacaval shunts. In
addition, there were 11 (18.3%) arterial reconstructions
(seven hepatic artery and four superior mesenteric artery).
Within the primary repairs, 18 were repaired by venorrha-
phy, whereas 19 were reconstructed by an end-to-end
anastomosis. For the autologous and CryoVein bypass
groups, these too were reconstructed in an end-to-end
fashion (Table II).
Table II. Distribution of the different types of vascular
reconstructions (VRs)
Venous N ¼ 49, No. (%)
Primary repair 37 (61.7)
Vein patch 3 (5)
Autologous reconstruction 3 (5)
CryoVein 4 (6.7)
Portacaval shunts 2 (3.3)
Arterial N ¼ 11, No. (%)
Primary reconstruction
(superior mesenteric artery)
4 (36.3)
Primary reconstruction and reimplantation
(right hepatic artery)
7 (63.6)
Table III. Unadjusted overall survival with 30-day
mortality and 1-year survival
Whipple
operation þ VR
(n ¼ 60), No. (%)
Whipple
resection only
(n ¼ 87), No. (%)
P
value
Survival, days
(months)
575.28 (18.9) 682.5 (22.4) .172
Intraoperative death 1/60 (1.6) 0/87 (0)
30-day mortality 3/60 (5) 3/87 (3.4) .699
1-year survival 42 (71.1) 61 (70.11) .981
VR, Vascular reconstruction.
Fig 2. Kaplan-Meier survival curve demonstrating a statistical
difference at 5 years with censored analysis. Data points include
absolute number of patients within each time interval as well as
standard error at each interval.
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(18.9 months) 6 494 days, with 12 patients still alive. In
comparison, the PD-only group had a mean survival of
682.5 days (22.4 months) 6 599.4 days. The 1-year sur-
vival for both surgical groups was 71.1% and 70.11%,
respectively (P ¼ .745; Table III). Kaplan-Meier survival
curve demonstrates no statistical signiﬁcance at 1 year
and 3 years between the groups. However, a disparity be-
tween the groups was established by year 4 and proved
to be statistically signiﬁcant at 5 years with a P value of
.011 in favor of longer survival within the PD-only group
(Fig 2). In addition, the survival of the VR group far ex-
ceeds that of the nationwide average for patients who
receive palliative chemoradiation without surgery.11-14
The VR group had one intraoperative death (1.6%)
compared with none in the PD-only group. The 30-day
mortality was 5.0% vs 3.4% (P ¼ .776), whereas the 90-
day mortality was 8.3% vs 4.5% (P ¼ .727). Neoadjuvant
chemotherapy was far more common within the VR group
compared with the PD-only group (39.7% vs 12.4%,
respectively). This subgroup had an even greater survival
of 594 days, with 0% 30-day mortality and 4.3% 90-day
mortality.
Bivariate and multivariate analyses were performed in
an attempt to ﬁnd any prognostic factors that may ac-
count for the statistical difference seen at 5 years on the
Kaplan-Meier survival curve. No statistically signiﬁcant
data were found; however, there appears to be a trend to-
ward positive margins being a prognostic factor as 22% of
patients had positive margins in the VR group, whereas
only 11% had positive margins in the PD-only group.
An increased odds ratio was also seen in lymph node sta-
tus, but again the conﬁdence interval was too large to
show signiﬁcance.
Lengths of stay were equivalent at 15.8 days for the VR
group and 16.75 days for the PD-only group (P ¼ .604).
By the Clavien-Dindo classiﬁcation system for complica-
tions,15 51.6% of the PD þ VR group and 57.5% of the
PD-only group had grade II or greater complications,
with no statistically signiﬁcant difference found between
the two groups. Perioperative 30-day venous thrombosiswas 6.1% (three of 49), and there were no arterial throm-
boses (zero of 11). Long-term results demonstrated four
additional thromboses within the venous group. Excluding
the acute thrombosis patients, mean survival for the
delayed thrombosis patients was 688 days.
DISCUSSION
Adenocarcinoma of the pancreas is the ﬁfth leading
cause of cancer death in the United States, with an
incidence and death rate nearly equivalent.16 Even with
the advent of chemotherapy and radiation therapy, the
5-year survival for all stages of pancreatic adenocarcinoma
is still at a dismal rate of 5%. Because so many pancreatic
tumors are locally advanced by the time they are diag-
nosed, more aggressive surgical resections have been
adopted in an effort to improve patient outcomes and
to give more than 20% of the pancreatic cancer popula-
tion a chance at a curative resection. It has been well
established that an R0 resection will have a better
outcome than an R1 or R2 resection.17,18 Without a
more aggressive resection, it can be argued that the likeli-
hood for a curative surgery is minute and therefore
should not even be attempted.
Several institutional series have demonstrated the feasi-
bility of margin-negative resection and VR, with acceptable
JOURNAL OF VASCULAR SURGERY
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lated PD only.7,8,19-23 They have all concluded that there is
likely to be a survival beneﬁt because of the improved abil-
ity to perform an R0 resection, especially of microscopic
disease in the perineural and perivascular tissue at the retro-
peritoneal margin.
In contrast to these ﬁndings, there have been studies
arguing against the resection of pancreatic adenocarcinoma
that involves the surrounding major vasculature. A multi-
center, retrospective analysis done in China found a signif-
icantly lower complication rate in the PD group compared
with the PD þ VR group (8.2% vs 23.5%, respectively) as
well as a lower mortality rate (3.0% vs 6.7%, respectively).24
In conjunction with this publication was a National Surgi-
cal Quality Improvement Program database analysis per-
formed by Castleberry et al8 that demonstrated
signiﬁcantly greater risk-adjusted mortality (5.7% vs 2.9%,
respectively) and overall morbidity (39.9% vs 33.3%,
respectively) in the PD þ VR group.
Our single-institution study has been able to reafﬁrm
the equivalent survival between the vascular resection
cohort and those who received PD only. This study does
have some obvious limitations. This includes its being a
retrospective, single-institution study with evolving proto-
col for borderline resectable disease. In addition, the power
of our study is weaker than that of a large database review
as our patient population is limited. However, unlike other
studies published in the literature, our study was able to
compare two groups equivalent in stage and type without
signiﬁcantly diminishing the power of the study. Patients
with stage I lesions or who have other types of neoplasms,
such as intraductal papillary mucinous neoplasms,
mucinous cystic neoplasms, neuroendocrine tumors, or
ampullary carcinoma, have been proved to have greater
survival than patients with pancreatic adenocarcinoma
with vascular invasion. Not only does this study show no
statistical difference between the two groups of patients
compared, it also displays a signiﬁcantly greater survival
than the national median survival for patients with stage
III disease who receive medical management only (chemo-
radiation), which is 10 to 12 months.25
Throughout the literature, it has been established that
performing an R0 resection is the most important aspect of
survival after PD. Studies that retrospectively examine the
presence or absence of vascular resection as a prognostic
factor for survival should include only patients who have
undergone a complete gross resection (R0 or R1).26 All pa-
tients within this study had an R0 or R1 resection, with
79.3% having an R0 resection. In the patients who had a
positive margin, median survival was signiﬁcantly less at
412 days, conﬁrming the importance of this factor for sur-
vival and not the vascular resection itself.
The most signiﬁcant complication of concern with this
surgical procedure is venous or arterial thrombosis after
reconstruction. This was evaluated with duplex ultrasound
initially postoperatively, followed by computed tomography
imaging. There are few publications that identify their
thrombosis rate; however, it ranges from 3% to 12%. Weshow a total thrombosis rate of 11.6%, with three acute
thromboses occurring within the ﬁrst 30 days postopera-
tively and four being delayed. Two thirds of our patients
with portal vein thrombosis expired while in the hospital.
Those with delayed thrombosis still had a survival greater
than with palliative care. This is likely due to the formation
of a collateral portal venous system supporting the venous
return to the liver.
A primary repair will almost always be possible; howev-
er, as can be seen in our limited experience, alternative re-
constructions can be successfully used. It is possible to
perform an end-to-end anastomosis even after excision of
as much as 4 cm of the portal vein, superior mesenteric
vein, or the conﬂuence of these vessels.19 For cases in
which this cannot be safely done, an autologous conduit
would be the next recommendation. Internal jugular,
femoral, and saphenous veins constructed as a spiral graft
can be used as they have diameters similar to the diameter
of the portal vein and therefore will match up appropri-
ately. The diameter of the anastomosis must be within
75% of the inﬂow vessel diameter, and normal ﬂow in the
portal venous system can be conﬁrmed by Doppler ultra-
sound evaluation.19 Should a patient not have any
adequate autologous vein to use, polytetraﬂuoroethylene
(PTFE) or CryoVein is a reasonable choice. The median
survival for our CryoVein patients (n ¼ 4) was
503.25 days, with two of the patients still alive. There
was one episode of acute graft thrombosis (25%), but all
other morbidity rates were equivalent. PTFE was not
used in this study; however, it has been reported as a
reasonable choice with nearly equivalent morbidity and
mortality rates (21.2% and 6.1%, respectively). Compared
with our ﬁndings, there was a higher thrombosis rate
(14.2% vs 11.6%). In addition, the investigators identiﬁed
no graft infections, which is of most concern because PD
is a clean-contaminated case.27 Further analyses with a
greater number of patients comparing PTFE and CryoVein
will be necessary to conclude which alternative conduit is
best if autologous vein is not a suitable choice.
The signiﬁcance of operating on pancreatic adenocarci-
noma with arterial invasion has not been clearly established
because most of these advanced tumors have already
metastasized and therefore have become inoperable. A tu-
mor would be considered not resectable if it had more than
180-degree encasement of the right hepatic or an aberrant
right hepatic. In locally advanced cases, arterial reconstruc-
tion, although safe, is a difﬁcult procedure compared with
portal vein reconstruction and is associated with an
increased risk of complications when it is conducted simul-
taneously with pancreatic resections.28 In our limited pop-
ulation (n ¼ 11), we were able to show an extended
survival compared with other T3 pancreatic adenocarci-
nomas. Invasion of the surrounding arterial vessels prob-
ably reﬂects an advanced stage of disease and is associated
with higher positive peripancreatic resection margins.26
The four cases that involved the superior mesenteric artery
were found intraoperatively, and therefore resection
and reconstruction were performed. Had this been seen
JOURNAL OF VASCULAR SURGERY
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intervention. Our increased survival may have been due
to the fact that 36.3% of this group received neoadjuvant
chemotherapy.
The role of the vascular surgeon has been recently
questioned in regard to PD þ VR. A retrospective review
demonstrated no difference in morbidity and mortality
regardless of whether the vascular service was involved;
however, operative time and blood transfusion were signif-
icantly increased when vascular surgery assisted in the pro-
cedure.9 It can be argued that this is a biased conclusion, as
the study was not able to identify the complexity of the
cases, the severity of disease, or the number of cases per-
formed at a particular hospital. All 60 cases at our institu-
tion involved vascular surgery. The argument in favor of
having an established service to care for these cases is that
it allows consistency and comfortability with the operation.
Prolonged clamp times can result in venous engorgement
of the small intestine, leading to the development of meta-
bolic acidosis.19 Portal vein or hepatic artery clamping may
also result in prolonged hepatic ischemia, and therefore
rapid reconstruction will be a necessity. Vascular surgery
involvement has been promoted in one other study arguing
that a vascular surgeon will be most important in lower vol-
ume centers to achieve outcomes comparable to those of
high-volume centers.29 It is our recommendation that a
surgeon experienced in vascular repairs be the individual
to perform the repair or reconstruction, as this has proved
to be successful at our institution.
CONCLUSIONS
PD þ VR is a reasonable approach for T3NO and
T3N1 pancreatic adenocarcinoma that invades the
venous or arterial vasculature. Our favorable results after
resection and VR compared with the survival after PD
only and compared with palliative therapy documented
in the literature strongly suggest that an aggressive surgi-
cal approach can improve survival in high-volume
institutions.
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2012;26:685-92.Submitted Jun 10, 2014; accepted Sep 5, 2014.DISCUSSIONDr Peter Lawrence (Los Angeles, Calif). I assume that most
of your patients get preoperative imaging with computed tomog-
raphy (CT)/computed tomography angiography or magnetic
resonance imaging/magnetic resonance angiography. Tell us
what the appropriate cross-sectional imaging workup is preopera-
tively, to look at vascular anatomy. Should every patient who is a
candidate for a Whipple have one of those imaging studies?
Dr Michael Sgroi. At our institution, every patient does
receive a triphasic CT scan, allowing the vascularity as well as tu-
mor involvement to be recognized. When possible, because the
vascular surgery service within our university performs all of the
operations, they are given these images preoperatively. So it is
our recommendation that all patients receive imaging.
Dr John Blebea (Tulsa, Okla). Can you tell us more about
the outcomes of these vascular reconstructions and their patency?
Were they followed postoperatively, and if so, using what
modalitydultrasound or CT scanning in conjunction with their
cancer follow-up?
Dr Sgroi. All patients did receive a duplex to evaluate for por-
tal vein thrombosis or arterial thrombosis postoperatively within
the vascular group. In addition to that, the hepatobiliary service
also would have regular CT scans to evaluate for any recurrence,
particularly in T3 lesions because it is elevated.
In addition to that, with the complications, we did have an
11.6% portal vein thrombosis rate, three of which were in the acute
setting and four that were delayed. Two of the three that occurred
in the acute setting were part of our 30-day mortality. With the
ones that had delayed thrombosis, those actually had survival
that was equivalent to the rest of our vascular reconstruction
group.
Dr Hasan Dosluoglu (Buffalo, NY). One question is that
years ago, I think, that the Hopkins group already showed that
when you try to resect these for cure, yet you leave a positive
microscopic margin behind, the patients still do better than just
leaving it alone.
Now, what you don’t have here are the patients that
you backed out without resection, and how they compared tothose with positive margins after this aggressive vascular
reconstruction.
When you group all patients having positive and negative mar-
gins together, it dilutes the data. What we’re really looking for is,
after all that effort, was it all worth it, when you did all that and still
had positive margins; and it may have been the case.
Dr Sgroi. Thank you for that question and actually that
brings up a great point. For these types of cases, it’s been proven
in the literature that palliative care for T3 lesions that have vascular
involvement is approximately 10 months. So we’re giving about an
80% increase in their overall survival. So we do believe even with
that R1 resection that this is a good procedure to perform.
Dr Rabih Chaer (Pittsburgh, Pa). We’re oftentimes asked to
harvest the jugular vein with a facial vein pedicle in order to perfuse
the splenic vein, in addition to the portal vein. Do you think this
has any advantage in terms of graft patency or cancer survival?
Dr Sgroi. We were actually very liberal about ligating the
splenic vein. If they had sinistral hypertension, then obviously we
would do our best not to. But we found that we were able to
get more length during our dissection and be able to perform a pri-
mary repair, so we actually did quite a bit of just ligation of that
splenic vein.
Dr William Quinones-Baldrich (Los Angeles, Calif). I think
it is critical that vascular surgery be involved prior to the procedure
as it is much more difﬁcult to decide the best alternative when one
is called during the operation. It is best to have a team that is dedi-
cated to evaluate and plan these complex procedures. My question
is: How many of these cases were you asked to evaluate preopera-
tively? How often were you called in the middle of the procedure?
Dr Sgroi. Thank you for your comment and your question.
We agree with you that if preoperatively the vascular surgeons
can know, that was attempted. I can tell you from reading the
operative reports that the only ones I can recognize for which
we were not called were the superior mesenteric artery involve-
ment, because those were ones that if that was found preopera-
tively, the resection wouldn’t have actually been done. So in
general we were always told prior to going to the operating room.
